Life after HSCT: Survivorship and long-term issues

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hematopoietic stem cell transplant (HSCT) is a curative therapeutic option for not just hematologic malignancies but also many nonmalignant conditions such as beta thalassemia, sickle cell disease, metabolic disorders, and certain primary immunodeficiencies. Continued advances in the HSCT techniques, expansion of indications for HSCT, and tremendous progress in supportive care strategies and management of HSCT-related complications have collectively resulted in an expanding population of survivors of HSCT. Progress and expansion of alternative donor hematopoietic stem cell (HSC) sources (e.g., umbilical cord blood, haploidentical donors) are resulting in a continually increasing amount of HSCTs performed in children per year. These survivors are at risk of developing treatment-related late effects, and two-thirds of the HSCT survivors will develop at least one chronic health condition. The direct impact of these long-term effects on the morbidity and mortality of the HSCT survivors makes risk-based and exposure-related screening for these late effects a critical part of their care. This chapter reviews the most common secondary neoplasms seen in survivors of HSCT during childhood and adolescence. This chapter will also discuss the HSCT-associated long-term complications affecting the cardiac, pulmonary, endocrine, musculoskeletal, renal, and neurocognitive systems. Screening recommendations are also included.

Original languageEnglish (US)
Title of host publicationHematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist
PublisherSpringer International Publishing
Pages385-401
Number of pages17
ISBN (Electronic)9783319631462
ISBN (Print)9783319631448
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hematopoietic Stem Cells
Survival Rate
Transplants
Survivors
beta-Thalassemia
Sickle Cell Anemia
Hematologic Neoplasms
Blood Donors
Fetal Blood
Tissue Donors
Morbidity
Kidney
Lung
Mortality
Health
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Dandekar, S. (2017). Life after HSCT: Survivorship and long-term issues. In Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist (pp. 385-401). Springer International Publishing. https://doi.org/10.1007/978-3-319-63146-2_27
Dandekar, Smita. / Life after HSCT : Survivorship and long-term issues. Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing, 2017. pp. 385-401
@inbook{3918291364ef425499358d162fa3637d,
title = "Life after HSCT: Survivorship and long-term issues",
abstract = "Hematopoietic stem cell transplant (HSCT) is a curative therapeutic option for not just hematologic malignancies but also many nonmalignant conditions such as beta thalassemia, sickle cell disease, metabolic disorders, and certain primary immunodeficiencies. Continued advances in the HSCT techniques, expansion of indications for HSCT, and tremendous progress in supportive care strategies and management of HSCT-related complications have collectively resulted in an expanding population of survivors of HSCT. Progress and expansion of alternative donor hematopoietic stem cell (HSC) sources (e.g., umbilical cord blood, haploidentical donors) are resulting in a continually increasing amount of HSCTs performed in children per year. These survivors are at risk of developing treatment-related late effects, and two-thirds of the HSCT survivors will develop at least one chronic health condition. The direct impact of these long-term effects on the morbidity and mortality of the HSCT survivors makes risk-based and exposure-related screening for these late effects a critical part of their care. This chapter reviews the most common secondary neoplasms seen in survivors of HSCT during childhood and adolescence. This chapter will also discuss the HSCT-associated long-term complications affecting the cardiac, pulmonary, endocrine, musculoskeletal, renal, and neurocognitive systems. Screening recommendations are also included.",
author = "Smita Dandekar",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-63146-2_27",
language = "English (US)",
isbn = "9783319631448",
pages = "385--401",
booktitle = "Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist",
publisher = "Springer International Publishing",

}

Dandekar, S 2017, Life after HSCT: Survivorship and long-term issues. in Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing, pp. 385-401. https://doi.org/10.1007/978-3-319-63146-2_27

Life after HSCT : Survivorship and long-term issues. / Dandekar, Smita.

Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing, 2017. p. 385-401.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Life after HSCT

T2 - Survivorship and long-term issues

AU - Dandekar, Smita

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Hematopoietic stem cell transplant (HSCT) is a curative therapeutic option for not just hematologic malignancies but also many nonmalignant conditions such as beta thalassemia, sickle cell disease, metabolic disorders, and certain primary immunodeficiencies. Continued advances in the HSCT techniques, expansion of indications for HSCT, and tremendous progress in supportive care strategies and management of HSCT-related complications have collectively resulted in an expanding population of survivors of HSCT. Progress and expansion of alternative donor hematopoietic stem cell (HSC) sources (e.g., umbilical cord blood, haploidentical donors) are resulting in a continually increasing amount of HSCTs performed in children per year. These survivors are at risk of developing treatment-related late effects, and two-thirds of the HSCT survivors will develop at least one chronic health condition. The direct impact of these long-term effects on the morbidity and mortality of the HSCT survivors makes risk-based and exposure-related screening for these late effects a critical part of their care. This chapter reviews the most common secondary neoplasms seen in survivors of HSCT during childhood and adolescence. This chapter will also discuss the HSCT-associated long-term complications affecting the cardiac, pulmonary, endocrine, musculoskeletal, renal, and neurocognitive systems. Screening recommendations are also included.

AB - Hematopoietic stem cell transplant (HSCT) is a curative therapeutic option for not just hematologic malignancies but also many nonmalignant conditions such as beta thalassemia, sickle cell disease, metabolic disorders, and certain primary immunodeficiencies. Continued advances in the HSCT techniques, expansion of indications for HSCT, and tremendous progress in supportive care strategies and management of HSCT-related complications have collectively resulted in an expanding population of survivors of HSCT. Progress and expansion of alternative donor hematopoietic stem cell (HSC) sources (e.g., umbilical cord blood, haploidentical donors) are resulting in a continually increasing amount of HSCTs performed in children per year. These survivors are at risk of developing treatment-related late effects, and two-thirds of the HSCT survivors will develop at least one chronic health condition. The direct impact of these long-term effects on the morbidity and mortality of the HSCT survivors makes risk-based and exposure-related screening for these late effects a critical part of their care. This chapter reviews the most common secondary neoplasms seen in survivors of HSCT during childhood and adolescence. This chapter will also discuss the HSCT-associated long-term complications affecting the cardiac, pulmonary, endocrine, musculoskeletal, renal, and neurocognitive systems. Screening recommendations are also included.

UR - http://www.scopus.com/inward/record.url?scp=85043348151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043348151&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-63146-2_27

DO - 10.1007/978-3-319-63146-2_27

M3 - Chapter

AN - SCOPUS:85043348151

SN - 9783319631448

SP - 385

EP - 401

BT - Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist

PB - Springer International Publishing

ER -

Dandekar S. Life after HSCT: Survivorship and long-term issues. In Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing. 2017. p. 385-401 https://doi.org/10.1007/978-3-319-63146-2_27